Trial Profile
An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia; Severe acute respiratory syndrome
- Focus Therapeutic Use
- Acronyms TOCI-RE
- 20 Oct 2020 Results published in the JAMA Internal Medicine
- 18 Jun 2020 Status changed from recruiting to discontinued.
- 09 Apr 2020 New trial record